Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

Schizophrenia Research

Volumn 66, Issue 2-3, 2004, Pages 143-150

  Buckley, Peter F ^a   Goldstein, Jeffrey M ^b   Emsley, Robin A ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Antipsychotic; Haloperidol; Quetiapine; Schizophrenia

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; QUETIAPINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0347991819     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2003.06.001     Document Type: Article

References (33)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 1994;American Psychiatric Association, American Psychiatric Press, Washington, DC.
2. Arvanitis L.A., Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry. 42(4):1997;233-246.
3. Azorin J.M., Spiegel R.et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry. 158(8):2001;1305-1313.
4. Barnes T.R.E., Schulz S., Buckley P. Treatment refractory schizophrenia. Hirsch S., Weinberger D. Schizophrenia. 2003;489-516 Blackwell, New York, NY.
5. Bondolfi G., Dufour H.et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psychiatry. 155(4):1998;499-504.
6. Brecher M., Rak I.W.et al. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int. J. Psychiatry Clin. Pract. 4:2000;287-291.
7. Buckley P.F. Broader therapeutic uses for atypical antipsychotic medications. Biol. Psychiatry. 2001;912-924.
8. Buckley P., Miller A.et al. When symptoms persist: clozapine augmentation strategies. Schizophr. Bull. 27(4):2001;615-628.
9. Chakos M., Lieberman J.et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 158(4):2001;518-526.
10. Chinchilla A., Vega M.et al. A long-term treatment with 'Seroquel' (quetiapine) in a severe schizophrenia patient. Eur. Neuropsychopharmacol. 7(Suppl. 2):1997;S198-S199.
11. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr. Bull. 23(4):1997;663-774.
12. Conley R.R., Tamminga C.A.et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry. 155(7):1998;914-920.
13. Conley R.R., Tamminga C.A.et al. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol. Psychiatry. 46(1):1999;73-77.
14. Copolov D.L., Link C.G.et al. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol. Med. 30(1):2000;95-105.
15. Emsley R.A., Oosthuisen P. The new and evolving pharmacotherapy of schizophrenia. Psychiatr. Clin. North Am. 26(1):2003;141-163.
16. Emsley R.A., Raniwalla J.et al. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol. 15(3):2000;121-131.
17. Essock S.M., Frisman L.K.et al. Parmacoeconomics of schizophrenia. Davis K. Neuropsychopharmacology: A Fifth Generation of Progress. 2002;Raven Press, New York.
18. Flynn S.W., MacEwan G.W.et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 31(1):1998;25-29.
19. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153(3):1996;321-330.
20. Kane, J.M., 2003. Aripiprazole for treatment-refractory schizophrenia. Presentation at the Annual meeting of the American Psychiatric Association, San Fransico, May.
21. Kane J., Honigfeld G.et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45(9):1988;789-796.
22. Kane J.M., Marder S.R., Schooler N.R., Wirshing W.C., Umbricht D., Baker R.W., Wirshing D.A., Safferman A., Ganguli R., McMenuman M., Borenstein M. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry. 58(10):2001;965-972.
23. Kasper S., Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert. Opin. Pharmacother. 1(4):2000;783-801.
24. Klieser E., Lehmann E.et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 15(1, Suppl. 1):1995;45S-51S.
25. Koziupa D. The efficacy of quetiapine in relieving persistent symptoms in a patient with poor response to both conventional and atypical antipsychotic therapy. J. Clin. Psychol. 60(Suppl. 23):1999;13.
26. Martin J., Gomez J.C.et al. Olanzapine in treatment-refractory schizophrenia: results of an open label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J. Clin. Psychiatry. 58(11):1997;479-483.
27. Reese S., Flynn S.et al. Varying definitions of treatment refractoriness and treatment response influence assessment of clinical value of clozapine. Schizophr. Res. 49:2001;242-243.
28. Schooler N.R., Marder S.R., Kane J.M.et al. Clozapine and risperidone in moderately refractory schizophrenia: a six month double-blind comparison. Schizophr. Res. 60(1):2003;302.
29. Tollefson G.D., Birkett M.A.et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry. 49(1):2001;52-63.
30. Volavka J., Czobor P.et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 159(2):2002;255-262.
31. Voruganti L., Cortese L.et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 43(2-3):2000;135-145.
32. Wahlbeck K., Cheine M.et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry. 156(7):1999;990-999.
33. Wirshing D.A., Marshall B.D. Jr.et al. Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry. 156(9):1999;1374-1379.